Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

ABSTRACT:

Background

There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.

Objective

The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.

Methods

A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions

SUBMITTER: Gonzalez-Robles C 

PROVIDER: S-EPMC12273612 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature